A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?

To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004–2012 (<i>n</i>...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cheng-Hsien Lin, Yu-Hsuan Shih, Tsung-Chih Chen, Cheng-Wei Chou, Chiann-Yi Hsu, Chieh-Lin Jerry Teng
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	lymphoma hemophagocytic lymphohistiocytosis overall survival performance status Medicine R
Acceso en línea:	https://doaj.org/article/e1d2ec4442874c638b5f5533c79ff017
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1d2ec4442874c638b5f5533c79ff017
record_format	dspace
spelling	oai:doaj.org-article:e1d2ec4442874c638b5f5533c79ff0172021-11-11T17:44:02ZA Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?10.3390/jcm102151142077-0383https://doaj.org/article/e1d2ec4442874c638b5f5533c79ff0172021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/5114https://doaj.org/toc/2077-0383To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004–2012 (<i>n</i> = 30) and 2013–2021 (<i>n</i> = 26). Our study showed that the clinical characteristics of lymphoma-associated HLH did not substantially change over the past two decades. However, more patients diagnosed in 2013–2021 were tested for Epstein–Barr virus than those diagnosed in 2004–2012 (69.3% vs. 33.3%; <i>p</i> = 0.021). In addition, Eastern Cooperative Oncology Group performance status 3–4 (hazard ratio (HR): 5.38; 95% confidence intervals (CI): 2.49–11.61; <i>p</i> < 0.001) and jaundice (HR: 2.91; 95% CI: 1.37–6.18; <i>p</i> = 0.006) were poor prognostic factors for lymphoma-associated HLH. With a comparable response rate of lymphoma treatment, patients treated in 2013–2021 had a numerically greater median OS than those treated in 2004–2012 (23.6 ± 19.8 vs. 9.7 ± 4.5 months). However, the difference was not statistically significant (<i>p</i> = 0.334). In conclusion, early diagnosis and tailored treatments that balance efficacy and adverse events remain the key to obtaining a better outcome in lymphoma-associated HLH.Cheng-Hsien LinYu-Hsuan ShihTsung-Chih ChenCheng-Wei ChouChiann-Yi HsuChieh-Lin Jerry TengMDPI AGarticlelymphomahemophagocytic lymphohistiocytosisoverall survivalperformance statusMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5114, p 5114 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lymphoma hemophagocytic lymphohistiocytosis overall survival performance status Medicine R
spellingShingle	lymphoma hemophagocytic lymphohistiocytosis overall survival performance status Medicine R Cheng-Hsien Lin Yu-Hsuan Shih Tsung-Chih Chen Cheng-Wei Chou Chiann-Yi Hsu Chieh-Lin Jerry Teng A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
description	To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004–2012 (<i>n</i> = 30) and 2013–2021 (<i>n</i> = 26). Our study showed that the clinical characteristics of lymphoma-associated HLH did not substantially change over the past two decades. However, more patients diagnosed in 2013–2021 were tested for Epstein–Barr virus than those diagnosed in 2004–2012 (69.3% vs. 33.3%; <i>p</i> = 0.021). In addition, Eastern Cooperative Oncology Group performance status 3–4 (hazard ratio (HR): 5.38; 95% confidence intervals (CI): 2.49–11.61; <i>p</i> < 0.001) and jaundice (HR: 2.91; 95% CI: 1.37–6.18; <i>p</i> = 0.006) were poor prognostic factors for lymphoma-associated HLH. With a comparable response rate of lymphoma treatment, patients treated in 2013–2021 had a numerically greater median OS than those treated in 2004–2012 (23.6 ± 19.8 vs. 9.7 ± 4.5 months). However, the difference was not statistically significant (<i>p</i> = 0.334). In conclusion, early diagnosis and tailored treatments that balance efficacy and adverse events remain the key to obtaining a better outcome in lymphoma-associated HLH.
format	article
author	Cheng-Hsien Lin Yu-Hsuan Shih Tsung-Chih Chen Cheng-Wei Chou Chiann-Yi Hsu Chieh-Lin Jerry Teng
author_facet	Cheng-Hsien Lin Yu-Hsuan Shih Tsung-Chih Chen Cheng-Wei Chou Chiann-Yi Hsu Chieh-Lin Jerry Teng
author_sort	Cheng-Hsien Lin
title	A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_short	A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_full	A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_fullStr	A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_full_unstemmed	A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
title_sort	decade of lymphoma-associated hemophagocytic lymphohistiocytosis: does the outcome improve?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e1d2ec4442874c638b5f5533c79ff017
work_keys_str_mv	AT chenghsienlin adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT yuhsuanshih adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT tsungchihchen adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chengweichou adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chiannyihsu adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chiehlinjerryteng adecadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chenghsienlin decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT yuhsuanshih decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT tsungchihchen decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chengweichou decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chiannyihsu decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove AT chiehlinjerryteng decadeoflymphomaassociatedhemophagocyticlymphohistiocytosisdoestheoutcomeimprove
_version_	1718432031261589504

A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?

Ejemplares similares